Related Experiment Video

Updated: Mar 9, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus

Maria D'Amato1, Chiara Maria Rapolla2, Edoardo Benedetti3

  • 1Department of Clinical and Experimental Medicine, UO Hematology, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy. m.damato@studenti.unipi.it.

Clinical and Experimental Medicine
|March 7, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AcalabrutinibBCL-2BTKChronic Lymphocytic LeukemiaIbrutinibPirtobrutinibSmall Lymphocytic LymphomaTargeted TherapiesVenetoclaxZanubrutinib

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K